Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 86Observational 5Expanded_access 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

PSR Ovarian Cancer With a BRCA Mutation 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

ulixertinib 1pegilodecakin 1olaparib 1niraparib 1balstilimab 1Proton Pump Inhibitors 1Hydrocortisone 1FANG vaccine 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Ovarian Neoplasms × olaparib × Clear all
NCT03079687 2017-10-25

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

AstraZeneca

Approved for marketing
Gynecologic

Carcinoma, Ovarian Epithelial, Neoplasms, Ovarian Diseases, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡